Amsterdam, The Netherlands, February 11, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it is scheduled […]
Amsterdam, The Netherlands, and Boston, Massachusetts, USA – February 4, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces […]
04 February 2019
Scott Holmes commences position as chief financial officerAmy Sullivan appointed senior vice president, corporate affairsBoth are based in Boston, Massachusetts Amsterdam, The Netherlands, and Boston, Massachusetts, USA – January 4, […]
04 January 2019
Amsterdam, The Netherlands, January 3, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it is scheduled […]
03 January 2019
Potential CHMP opinion moved from Q4 2018 into H1 2019Guidance for initial EU commercial launch in H2 2019 unchangedFDA meeting held under RMAT statusPhase 3 study on track with […]
12 October 2018
Strengthens Senior Management Team with Chief Human Resources Officer and General Counsel and Company Secretary Amsterdam, The Netherlands, September 6, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) […]
06 September 2018
Amsterdam, The Netherlands, August 31, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces its unaudited interim Financial […]
31 August 2018